EQ Equillium, Inc.
USHealthcareAs of 2026-07-09 16:00
Why EQ matters now
Equillium, Inc. (EQ) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.96 with -6.03% on the session and $105.1M in market capitalization; recent performance reads 1-month +72.32% and YTD +96.77%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-5.3M, and EPS of $-0.06. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -17.5%.
The latest indexable market news headline is "EQ Works Expands Multi-Year Partnership with Leading Canadian Publisher to Include SaaS License for ClearLake" from Accesswire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $6.50; recent insider activity includes Connelly Stephen filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.94
P/S
0.00
EV/EBITDA
-2.52
DCF Value
$0.32
FCF Yield
-17.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-61.4%
ROA
-30.2%
ROIC
-33.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-5.3M | $-0.06 |
| Q4 2025 | $0.00 | $-3.8M | $-0.04 |
| FY 2025 | $0.00 | $-22.4M | $-0.39 |
| Q3 2025 | $0.00 | $-4.2M | $-0.12 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$6.25
Target (Median)
$6.50
Target Range
$5.00 - $7.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.76
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.